Elsevier

Journal of Functional Foods

Volume 28, January 2017, Pages 138-146
Journal of Functional Foods

Dietary fucoidan improves metabolic syndrome in association with increased Akkermansia population in the gut microbiota of high-fat diet-fed mice

https://doi.org/10.1016/j.jff.2016.11.002Get rights and content

Highlights

Abstract

Emerging evidence shows that dietary fucoidan contribute to the prevention and treatment of diverse diseases. Here, using a mouse model, we first demonstrate a similar beneficial effect of two fucoidans from Laminaria japonica and Ascophyllum nodosum on diet-induced metabolic syndrome (MetS). Both fucoidans were found to significantly reduce body weight, fasting blood glucose, hepatic steatosis and systematic inflammation. To decipher the mechanism behind this therapeutic effect, the gut microbiota was analyzed as fucoidan is poorly absorbed after oral administration. Interestingly, we found that benign microbes which conferred benefits upon host wellbeing including Akkermansia muciniphila and short-chain fatty acid-producers such as Alloprevotella, Blautia and Bacteroides were highly enriched by fucoidans. Collectively, our study illustrates a novel application of fucoidan as an anti-MetS functional food and, from a gut microbiota perspective, sheds new insight into the mechanism by which unabsorbed polysaccharide exerts a system therapeutic effect.

Introduction

Recent years have witnessed a devastating worldwide epidemic of metabolic syndrome (MetS), a constellation of obesity, insulin resistance, dyslipidemia and hypertension (Beltrán-Sánchez et al., 2013, Kaur, 2014). Given the accumulating knowledge that gut microbiota plays a critical role in modulating metabolism, nutrition and immunity of its host (Nicholson et al., 2012, Tremaroli and Bäckhed, 2012), an evolving body of literature has linked gut dysbiosis, an imbalance of intestinal microbiota, to the development of obesity, insulin resistance and other characteristics of MetS (Cani et al., 2008, Ley et al., 2006, Ussar et al., 2015). Recently and more strikingly, some species of gut flora, including Enterobacter cloacae and Akkermansia muciniphila, were found to be causally associated with the development of MetS (Everard et al., 2013, Fei and Zhao, 2013, Shin et al., 2013). Mono-association of germ-free mice with E. cloacae causes fully-developed obesity and insulin resistance on a high-fat diet (HFD) while oral administration of A. muciniphila to HFD-fed mice remarkably enhanced glucose tolerance and attenuated systematic inflammation (Fei and Zhao, 2013, Shin et al., 2013). Combined with the fact that dietary interventions and pre- or probiotic treatment have been successfully used to prevent or alleviate MetS during the past few years (Delzenne, Neyrinck, Bäckhed, & Cani, 2011), these studies rationalize gut microbiota as a desired target for MetS management.

Fucoidans are a class of sulphated fucose-rich polysaccharides which are mainly found in edible brown seaweeds (Li, Lu, Wei, & Zhao, 2008). Naturally occurring fucoidan usually has two types of chain with type I chain composed of α (1  3) linked fucose and type II chain composed of altering α (1  3) and α (1  4) linked fucose (Cumashi et al., 2007). Since its first discovery by Kylin in 1913 (Li, Lu, Wei, & Zhao, 2008), research into fucoidans has continued to gain pace over years of study(Fitton, 2011, Fitton et al., 2015). Until now, substantial evidence has demonstrated an attractive array of bioactivities which makes fucoidan a promising candidate for drug and functional food development (Fitton et al., 2015). Recently, fucoidan stands out as a potential lever to attenuate MetS due to its desired properties including anti-inflammation (Lee et al., 2013), anti-diabetes (Shan et al., 2016) and anti-obesity (Kim, Jeon, & Lee, 2014). However, although this possibility has been proposed, no systematic study is currently available regarding to this issue. Besides, as for the mechanisms by which fucoidan improve glucose homeostasis and inhibit lipid accumulation, while down-regulation of peroxisome proliferator-activated receptor γ (Kim, Chang, & Lee, 2009) and up-regulation of total hormone sensitive lipase (Park, Jung, & Roh, 2011) have been documented, it is still difficult to explain the clinical efficacy of fucoidan owing to its extremely low bioavailability after oral administration (Irhimeh et al., 2005, Nagamine et al., 2014, Tokita et al., 2010). Lately, intake of unabsorbed polysaccharide from Ganoderma lucidum has been illustrated to protect against MetS by targeting gut microbiota (Chang et al., 2015). Considering that fucoidan is also largely unabsorbed in the gastrointestinal tract, this study indicates an underlying role for fucoidan in modulating gut microbiota during the treatment of obesity-related metabolic diseases. However, unfortunately, this hypothesis has been the subject of relatively few investigations.

In the present study, fucoidan from Laminaria japonica (FuL) with type I chain (Cumashi et al., 2007, Vishchuk et al., 2011) and fucoidan from Ascophyllum nodosum (FuA) with type II chain (Cumashi et al., 2007, Marais and Joseleau, 2001) were studied on their effects on host physiology and gut microbiota in mice with HFD-induced MetS. We found that both FuL and FuA profoundly attenuated body weight gain, improved glucose homeostasis and reduced systematic inflammation in diseased mice. Interestingly, combined with ameliorated MetS, both fucoidans altered the gut microbiota in a direction that favored the host. Altogether, our study provides a fresh perspective into the role of gut microbiota modulation during the treatment of MetS by fucoidan.

Section snippets

Chemicals and materials

The brown algae Ascophyllum nodosum and Laminaria japonica were sourced from Antofagasta (Chile) and Weihai (China) respectively. Both seaweeds were obtained from Gather Great Ocean Algae Industry Group Co., Ltd. (Qingdao, China) and authenticated by Prof. Xiang zhong Gong at Ocean University of China based on histological and morphological features. FuA and FuL were extracted and further purified as previously reported (Shan et al., 2016). Chemical compositions of FuA and FuL were determined

Chemical characterization of fucoidan

FuA from Ascophyllum nodosum with type II chain was found to have a molecular weight (MW) of 1330 kDa and sulfate content (SC) of 21.0% (Supplementary Table S2). In contrast, the MW and SC of FuL from Laminaria japonica with type I chain were found only to be 310 kDa and 18.4%, respectively (Supplementary Table S2). As for monosaccharide composition, expectedly, both FuA and FuL were dominated by fucose (Supplementary Table S2). However, FuA had a higher amount of GlcA (24.1%) while Gal (19.3%)

Discussion

Fucoidan has long been championed as a multifunctional marine polysaccharide with versatile activities (Li et al., 2008, Fitton, 2011, Fitton et al., 2015). However, its precise mechanism of action remains largely unclear although several different ones have been proposed. In light of the fact that gut microbiota can be manipulated by drugs and functional foods to improve human health and to treat disease (Chang et al., 2015, Jia et al., 2008), we extrapolate that fucoidan may have gut

Conclusions

In conclusion, our study demonstrated that fucoidan intervention can reduce MetS probably through its modulations of gut microbiota by selectively promote the growth of benign bacteria including Akkermansia and SCFA-producers. Based on preceding studies, we characterized a novel potential therapeutic role of fucoidan and for the first time we provided a deep analysis of gut microbiota alterations that occurred after fucoidan supplementation in the context of metabolic inflammation, obesity and

Conflict of interest

The authors declare no competing financial interests.

Acknowledgements

This work was supported in part by National Natural Science Foundation of China (31670811), NSFC-Shandong Joint Fund for Marine Science Research Centers (U1406402), National Science & Technology Support Program of China (2013BAB01B02), Special Fund for Marine Scientific Research in the Public Interest (201005024), Taishan scholar project special funds and Major Science and Technology projects in Shandong Province (2015ZDJS04002), Qingdao Basic & Applied Reaarch Project (165115JCH).

References (51)

  • P.D. Cani et al.

    Metabolic endotoxemia initiates obesity and insulin resistance

    Diabetes

    (2007)
  • P.D. Cani et al.

    Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice

    Diabetes

    (2008)
  • J.G. Caporaso et al.

    QIIME allows analysis of high-throughput community sequencing data

    Nature Methods

    (2010)
  • C.J. Chang et al.

    Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota

    Nature Communications

    (2015)
  • S.J. Creely et al.

    Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes

    American Journal of Physiology-endocrinology and Metabolism

    (2007)
  • A. Cumashi et al.

    A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds

    Glycobiology

    (2007)
  • N.M. Delzenne et al.

    Targeting gut microbiota in obesity: Effects of prebiotics and probiotics

    Nature Reviews Endocrinology

    (2011)
  • A. El Kaoutari et al.

    The abundance and variety of carbohydrate-active enzymes in the human gut microbiota

    Nature Reviews Microbiology

    (2013)
  • C.C. Evans et al.

    Exercise prevents weight gain and alters the gut microbiota in a mouse model of high fat diet-induced obesity

    PLoS One

    (2014)
  • A. Everard et al.

    Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity

    Proceedings of the National Academy of Sciences

    (2013)
  • N. Fei et al.

    An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice

    The ISME Journal

    (2013)
  • J.H. Fitton

    Therapies from fucoidan; multifunctional marine polymers

    Marine Drugs

    (2011)
  • J.H. Fitton et al.

    Therapies from fucoidan: An update

    Marine Drugs

    (2015)
  • L. Geurts et al.

    Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: Impact on apelin regulation in adipose tissue

    Frontiers in Microbiology

    (2011)
  • P. Hugon et al.

    Non contiguous-finished genome sequence and description of Alistipes obesi sp. nov

    Standards in Genomic Sciences

    (2013)
  • Cited by (197)

    View all citing articles on Scopus
    View full text